INBX Relative Valuation
INBX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INBX is overvalued; if below, it's undervalued.
Historical Valuation
Inhibrx Biosciences Inc (INBX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.21. The fair price of Inhibrx Biosciences Inc (INBX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：87.41
Fair
-15.58
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Inhibrx Biosciences Inc. (INBX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-11.09
EV/EBIT
Inhibrx Biosciences Inc. (INBX) has a current EV/EBIT of -11.09. The 5-year average EV/EBIT is -1.33. The thresholds are as follows: Strongly Undervalued below -6.83, Undervalued between -6.83 and -4.08, Fairly Valued between 1.41 and -4.08, Overvalued between 1.41 and 4.16, and Strongly Overvalued above 4.16. The current Forward EV/EBIT of -11.09 falls within the Strongly Undervalued range.
0.00
PS
Inhibrx Biosciences Inc. (INBX) has a current PS of 0.00. The 5-year average PS is 5.56. The thresholds are as follows: Strongly Undervalued below -70.03, Undervalued between -70.03 and -32.24, Fairly Valued between 43.35 and -32.24, Overvalued between 43.35 and 81.14, and Strongly Overvalued above 81.14. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Inhibrx Biosciences Inc. (INBX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Inhibrx Biosciences Inc. (INBX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Inhibrx Biosciences Inc (INBX) has a current Price-to-Book (P/B) ratio of 34.41. Compared to its 3-year average P/B ratio of 4.69 , the current P/B ratio is approximately 633.27% higher. Relative to its 5-year average P/B ratio of 4.69, the current P/B ratio is about 633.27% higher. Inhibrx Biosciences Inc (INBX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -68.04%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -68.04% , the current FCF yield is about -100.00% lower.
34.41
P/B
Median3y
4.69
Median5y
4.69
-11.89
FCF Yield
Median3y
-68.04
Median5y
-68.04
Competitors Valuation Multiple
The average P/S ratio for INBX's competitors is 0.00, providing a benchmark for relative valuation. Inhibrx Biosciences Inc Corp (INBX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of INBX increased by 467.60% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 0.00 to 0.00.
The secondary factor is the Margin Expansion, contributed -100.48%to the performance.
Overall, the performance of INBX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Inhibrx Biosciences Inc (INBX) currently overvalued or undervalued?
What is Inhibrx Biosciences Inc (INBX) fair value?
How does INBX's valuation metrics compare to the industry average?
What is the current P/B ratio for Inhibrx Biosciences Inc (INBX) as of Dec 05 2025?
What is the current FCF Yield for Inhibrx Biosciences Inc (INBX) as of Dec 05 2025?
What is the current Forward P/E ratio for Inhibrx Biosciences Inc (INBX) as of Dec 05 2025?